AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03467009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Enhanced Usual Care (EUC)
Description: EUC group participants will receive standardized information on cyberbullying.
Study NCT02593864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable-Stiffness Shoe
Description: A load-modifying variable-stiffness shoe previously shown to reduce joint loading
Study NCT02464111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment 1: Control
Description: No supplement provided.
Study NCT00262379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin beta (NeoRecormon®)
Description: • Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female
Study NCT02001883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Association low-dose statin and nutraceuticals
Study NCT01218178 — intervention group
Intervention type: DRUG
Intervention: Sodium bicarbonate plus NAC
Description: 154 mEq/L sodium bicarbonate (infusion rate of 3 ml/Kg for 1 hour followed by 1 ml/Kg for 6 hours) plus NAC (1200 mg bid for 48 hours)
Study NCT01218178 — intervention group
Intervention type: DRUG
Intervention: Saline hydration plus NAC
Description: 0.9% saline (1 ml/Kg for 12 hours) plus NAC (1200 mg bid for 48 hours)
Study NCT03467009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPACT Intervention- app
Description: Brief in-person + tailored, daily 8-week message secondary prevention intervention delivered via app.
Study NCT03338959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03338959 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02899078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02899078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02555501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDT + Low level laser
Description: Two days before the laser treatment, the side of the oral cavity chosen for the experimental treatment was pigmented with aqueous solution of 0.005% methylene blue. A ball of sterile cotton was soaked in the dye solution and placed in the center of the lesion. Photosensitizer remained in the place for 5 minutes (pre-irradiation period). Then, to activate the dye, the lesion was irradiated with red light (InGaAlP / phosphide and Indium, Gallium and potassium).~From the 3rd to the 10th day was carried out only laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
Study NCT02555501 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser
Description: Two days before the laser treatment, the lesion of the side of the oral cavity chosen for the control treatment was treated with ball of sterile cotton soaked in distilled water and the laser unit placed on the lesion without activation of the light. From the 3rd to the 10th day was carried out laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
Study NCT04044144 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Dietary Supplement
Description: Dietary supplement containing a combination of 8 probiotic strains
Study NCT01546272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insorb resorbable staples
Description: Subcutanous suture using resorbable staples
Study NCT01546272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl resorbable wire
Description: Subcutanous suture using resorbable wire
Study NCT01678976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: Tablets containing BIA 2-093 in doses of 300 and 600 mg
Study NCT01678976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIA 2-093
Description: Tablets containing BIA 2-093 in doses of 300 and 600 mg
Study NCT01678976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Tablets containing 300 mg and 600 mg of Trileptal®
Study NCT01678976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine
Description: Tablets containing 300 mg and 600 mg of Trileptal®
Study NCT02850302 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PET with FDG
Description: A PET with FDG will be performed before the treatment is started and after 6 cycles of chemotherapy.
Study NCT02850302 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tumor exome analysis
Description: A biopsy of the tumor will be performed before the treatment is started and after 6 cycles of chemotherapy. Tumor exome analysis will be performed before treatment is started and after 6 cycles of chemotherapy.
Study NCT04954482 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is an observation study, with no intervention
Study NCT00206726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab plus Fludarabine
Description: Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days
Study NCT03989869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate treatment
Description: Early Medical Abortion treatment, when ultrasound does not yet have conclusive signs of intrauterine pregnancy
Study NCT02185521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient assessment
Description: Patient clinician status assessment based on Hemodynamic Instability Indicator (HII) trend. The HII indicator combines existing data such as physiologic parameters (Heart Rate, HR; Blood Pressure, BP), laboratory measurements (Albumin; Hematocrit, HCT; Bicarbonate; White Blood Cell, WBC; Blood Urea Nitrogen, BUN), and ADT information (age). HII will be displayed on charting workstation (Workstation on Wheels, WOW). Nurse's role will be to observe the value of HII while accessing WOW desktop (during regular charting), interpret HII value, and share this information to the physician when indicative of potential patient hemodynamic instability to trigger patient clinical status assessment. This intervention is associated with Experimental Study Arm: visible HII.
Study NCT03751267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tuina (massage)
Description: Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
Study NCT00875758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removal of CSF through ventricular access device
Description: Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile + 2 standard deviations. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
Study NCT00875758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of CSF through a ventricular access device
Description: Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
Study NCT02099071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 1 mg
Study NCT02099071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 5 mg
Study NCT02099071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 20 mg
Study NCT02099071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 50 mg
Study NCT02099071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 100 mg
Study NCT02099071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 200 mg
Study NCT02099071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 500 mg
Study NCT02099071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 1000 mg
Study NCT04222517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incisional hernia repair by the mesh implant in sublay retromusuclar position
Description: Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark).
Study NCT04222517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incisional hernia repair by the mesh implant in sublay retromusuclar position with using a local hemostatic Hemoblock
Description: Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space. Used a local hemostatic Hemoblock 15 ml in this space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Used a local hemostatic Hemoblock 15 ml in subcutaneus space. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark).
Study NCT03422484 — intervention group
Intervention type: OTHER
Intervention: Detection and correction of medication error at hospital admission
Description: Detection and correction of medication error at hospital admission
Study NCT02099071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02464111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 2: Bolus (LNS)
Description: One LNS supplement provided in a single bolus dose in the morning
Study NCT00007007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Study NCT00007007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT01761071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)
Description: On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
Study NCT01761071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)
Description: On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
Study NCT01744145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventional 40-60
Description: This group will receive the intervention aged 40-60
Study NCT01744145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventional 60 and above
Description: This group will receive the intervention aged 60 and above.
Study NCT01758445 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiotherapy
Description: Radiation therapy will be given once a day. Minimum of 28 treatments and may receive 6-9 additional treatments as determined by protocol \& physician.
Study NCT01246466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid: AtriCure Bipolar System & EP ablation procedure
Description: AtriCure Bipolar System plus a catheter ablation
Study NCT00562900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic assisted cholecystectomy
Description: robotic assisted cholecystectomy
Study NCT00562900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy
Study NCT00877773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
Study NCT04153734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
Study NCT04153734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis Platinum
Description: In patients with non-squamous histology, cisplatin (75 mg/m2) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
Study NCT04153734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: In cisplatin-intolerable patients, carboplatin (AUC=6) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
Study NCT04153734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: In patients with non-squamous histology, pemetrexed (500 mg/m2) will be administered every 3 weeks until progression or 2 years after initiation (35 cycles) with pembrolizumab.
Study NCT02464111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 3: Divided Dose (LNS)
Description: One LNS supplement provided in 3 separate portions throughout the study visit
Study NCT04213989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexitouch Plus and Conservative Care
Description: A segmental, programmable, gradient advanced pneumatic compression device. The system consists of a controller unit and garments, and provides in-home manual lymphatic drainage therapy in the legs for approximately 1 hour daily. Conservative care may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
Study NCT04213989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Care
Description: May include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
Study NCT02552680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physical Exercise
Study NCT02552680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guideline
Description: Guideline on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
Study NCT02552680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Manual/brochure containing information about general health
Study NCT02023138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Focus group
Description: Two hours focus group to allow the participants to modify a clinical practice guideline recommendation
Study NCT02023138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus group
Description: Two hours focus group to allow the participants to modify a clinical practice guideline recommendation
Study NCT02023138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wiki
Description: A specially tailored interactive communication website (Wiki) to allow the participants to modify a clinical practice guideline recommendation
Study NCT02023138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wiki
Description: A specially tailored interactive communication website (Wiki) to allow the participants to modify a clinical practice guideline recommendation
Study NCT04788290 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Rabone D®, Once daily administered per the locally approved product information
Study NCT00440180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg qd for 4 months
Study NCT00440180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT04153734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: In patients with squamous histology, nab-paclitaxel (100 mg/m2, day 1, 8, 15, tri-weekly) will be administered until 4 cycles with pembrolizumab.
Study NCT01185431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ficus carica (Fig paste)
Description: Ficus carica paste 300g/day
Study NCT01185431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Placebo paste)
Description: Placebo composition 300g/day
Study NCT03055377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: N-acetylcysteine 1200 mg twice daily for 12 weeks (administered orally)
Study NCT03055377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
Study NCT04369820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: draw blood
Description: 40 mL blood sample will be taken within the first three days of hospitalization, a second sample will be taken between the 5th and 10th day of hospitalization and a third sample will be taken on the 10th day of hospitalization or the day of discharge if earlier.
Study NCT03393533 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group I
Description: Extraction third molar without the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
Study NCT03393533 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Group II
Description: Extraction third molar with the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
Study NCT03745820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB104
Description: Administered as specified in the treatment arm
Study NCT03745820 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study NCT04043390 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CRP and Molbio Truenat MTB
Description: A molecular assay to detect M tuberculosis DNA Truenat is currently undergoing the process of endorsement by the WHO.
Study NCT04043390 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CRP and Xpert ULTRA MTB/RIF
Description: A molecular assay to detect M tuberculosis DNA ULTRA is already endorsed by the WHO. However the tests are still considered experimental in Nigeria and Ethiopia.
Study NCT04043390 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standard test Xpert
Description: The investigators will use Xpert to compare its agreement with scheme 1 (CRP plus Truenat MTB) and scheme 2 (CRP plus ULTRA).
Study NCT04043390 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Culture as reference standard
Description: The investigators will use culture to assess the sensitivity of schemes 1 and 2
Study NCT00724880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel is stopped 5 days prior to surgery
Study NCT00724880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel is stopped 3 days prior to surgery
Study NCT00724880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel is stopped 0 days prior to surgery
Study NCT02292784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retosiban
Description: This is a safety follow-up study of infants and children exposed to retosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.